US0088753043 - Common Stock
NASDAQ:AIKI (8/16/2022, 5:17:36 PM)-0.07 (-1.11%)
|GICS Sector||Health Care|
|Earnings (Last)||05-16 2022-05-16/dmh||Earnings (Next)||08-23 2022-08-23/amc|
|Ins Owners||N/A||Inst Owners||13.66%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Aikido Pharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 4 full-time employees. AIkido Pharma Inc. is a biotechnology company, with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
AIKIDO PHARMA INC
One Rockefeller Plaza, 11Th Floor
New York City NEW YORK 10020
CEO: Anthony Hayes
/PRNewswire/ -- Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), announced the hiring of Carlos Aldavero as President of...
/PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") announced the formation of a wholly owned subsidiary with the purpose of making...
/PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company....
Novavax (NVAX) stock is in the news today as investors prepare for the results from the vaccine company's meeting with the FDA.
AIkido Pharma (AIKI) stock is skyrocketing on Tuesday but it's not due to any positive news from the biotechnology company.
Here you can normally see the latest stock twits on AIKI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.